Periprosthetic Bone Remodeling After Novel Short-Stem Neck-Sparing Total Hip Arthroplasty

Tran, Phong; Zhang, Benny X.; Lade, Justin A.; Pianta, Robert M.; Unni, R.; Haw, Chris S.

doi:10.1016/j.arth.2016.04.023

Cited by 13 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These are comparable to other studies using the Metha 1 stem, 3,7,8 or other short stems. 1,5,6 Pain values decreased to 0.4 of 10 points. The NAS is comparable to the more often used visual analog scale (VAS).…”

Section: Discussionmentioning

confidence: 85%

“…Over the years, dualenergy X-ray absorptiometry (DXA) became a proven method to examine changes of bone mineral density (BMD) around implants. [1][2][3][4][5][6][7][8][9] To describe changes of the interface between bone and femoral implants the Gruen zone system has been established as standard. Originally, it was developed for classifying zones of lucency on plain x-rays following the implantation of standard stems.…”

Section: Introductionmentioning

confidence: 99%

“…1,4,7 In contrast, other studies show equal expansions within lateral zones 1-3. 2,3,6 Thus, there is no common definition concerning the boundary within the lateral or medial zones. This makes it necessary to introduce a more detailed and defined system regarding the special demands of short stem investigations.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Bone remodelling around the Metha ® short stem implant – Clinical and dual-energy x-ray absorptiometry (DXA) results

Fischer¹,

Beckmann

Simank³

2017

Journal of Orthopaedics

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 85%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bone remodelling around the Metha ® short stem implant – Clinical and dual-energy x-ray absorptiometry (DXA) results

Fischer¹,

Beckmann

Simank³

2017

Journal of Orthopaedics

View full text Add to dashboard Cite

show abstract

“…Bone remodeling around the femoral stem after THA will cause periprosthesis bone loss, and periprosthetic fracture, which mainly, occurs in the first post-operative year. [ 2 , 3 ] Besides, aseptic loosening will increase the risk of revision hip arthroplasty. [ 4 ] Internal fixator is stiffer than bone tissue, and bears the majority of the load, thus bone is stress-shielded, resulting disuse atrophy.…”

Section: Introductionmentioning

confidence: 99%

Effect of risedronate on femoral periprosthetic bone loss following total hip replacement

Ren

Wang

2018

Medicine

View full text Add to dashboard Cite

Background:Recent study has reported that risedronate was effective in reducing periprosthesis bone loss after total hip arthroplasty (THA). The meta-analysis was performed to compare the clinical outcomes of THA with oral risedronate versus placebo.Methods:Electronic databases: PubMed (1950–March 2018), EMBASE (1974–March 2018), the Cochrane Central Register of Controlled Trials, Web of Science (1950–March 2018) were systematically searched. Two authors independently graded the methodological quality of each eligible study using the Cochrane Collaboration tool and extracted relevant data. Statistical heterogeneity among the trials were evaluated with chi-square and I-square tests. This meta-analysis was performed using STATA 14.0.Results:A total of 4 randomized controlled trials (RCTs) published between 2006 and 2015 were included in our study. The meta-analysis demonstrated that risedronate was associated with a significantly reduction of periprosthetic bone mineral density after THA. No increased postoperative complications were observed.Conclusion:Oral risedronate might reduce the periprosthetic bone resorption after cementless THA. Additionally, no severe adverse effects were observed. High-quality RCTs with large sample size were still required.

show abstract

“…Currently, periprosthetic bone loss (PBL) remains the major cause of aseptic loosening that results in implant failures [1]. Previous literature reported some widely accepted protocols for preventing and treating PBL, but no guideline has been proposed [2][3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Denosumab might prevent periprosthetic bone loss after total hip and knee arthroplasties: a review

Xu¹,

Qu³

et al. 2021

Arthroplasty

View full text Add to dashboard Cite

Total hip arthroplasty and total knee arthroplasty are extensively used for the treatment of the end-stage degenerative joint diseases. Currently, periprosthetic bone loss is still the major cause of aseptic loosening, resulting in implant failures. Previous literature introduced some widely accepted protocols for the prevention and treatment of periprosthetic bone loss, but no guideline has been proposed. Denosumab, a human monoclonal immunoglobulin G2 (IgG2) antibody, can inhibit bone resorption by binding to the receptor activator of nuclear factor kappa-B ligand (RANKL). This article reviews the present findings and evidence concerning the effect of denosumab on the periprosthetic bone loss after total hip arthroplasty and total knee arthroplasty. Overall, the current evidence suggests that denosumab is a promising agent for the treatment of periprosthetic bone loss.

show abstract

Periprosthetic Bone Remodeling After Novel Short-Stem Neck-Sparing Total Hip Arthroplasty

Cited by 13 publications

References 22 publications

Bone remodelling around the Metha ® short stem implant – Clinical and dual-energy x-ray absorptiometry (DXA) results

Bone remodelling around the Metha ® short stem implant – Clinical and dual-energy x-ray absorptiometry (DXA) results

Effect of risedronate on femoral periprosthetic bone loss following total hip replacement

Denosumab might prevent periprosthetic bone loss after total hip and knee arthroplasties: a review

Contact Info

Product

Resources

About